Mankind Pharma witnessed a 29% surge in consolidated net profit, reaching Rs 658.88 crore in the second quarter, ending September 2024. This growth was fueled by volume recovery and a strong performance in the chronic segment. Their revenue also saw a rise of 13.6%, reaching Rs 3,076.51 crore, attributed to operational leverage and steady revenue growth.
| Subscribe To Our Free Newsletter |
